EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application exemestane tablets USP, 25 mg. Aurobindo Pharma’s exemestane tablets are an AB-rated generic equivalent to the reference listed drug (RLD), AROMASIN Tablets, manufactured by Pfizer.

Exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer and treatment of advanced breast cancer in postmenopausal women, whose disease has progressed following tamoxifen therapy.

Exemestane ablets has an estimated market size of US $29 million for the twelve months ending March 2022, as per IQVIA.